Clinical Study
Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease
Table 1
Characteristics of the study groups.
| | | CAD group | Controls | |
| | Number of patients; females | 53 (9) | 53 (6) | 0.4 | | Age; years | 51.3 ± 7.8 (38 ÷ 65) | 42.03 ± 4.82 (35 ÷ 55) | <0.000001 | | Framingham Risk Score; % | 12.1 ± 6.4 (1.8 ÷ 28) | 4.9 ± 3.6 (0.2 ÷ 19.8) | <0.000001 | | BMI; kg/m2 | 29.4 ± 4.9 (19.5 ÷ 44.7) | 29.2 ± 3.8 (21.7 ÷ 40.7) | 0.81 | | Waist-hip ratio | 0.96 ± 0.06 (0.77 ÷ 1.09) | 0.94 ± 0.06 (0.74 ÷ 1.1) | 0.19 | | Overweight; (%) | 20 (37.73) | 28 (52.83) | 0.11 | | Obesity; (%) | 22 (41.45) | 18 (33.96) | 0.72 | | Hypertension; (%) | 37 (69.81) | 19 (35.84) | 0.0005 | | CAD; (%) | 53 (100) | — | — | | History of | | | | | Myocardial infarction; (%) | 7 (13.2) | — | — | | PCI; (%) | 9 (16.98) | — | — | | CABG; (%) | 1 (1.88) | — | — | | Smoking history | | | | | Whenever; (%) | 35 (66.04) | 27 (50.94) | 0.52 | | Number of pack-years | 25.75 ± 9.04 (1 ÷ 40) | 15.25 ± 7.04 (1 ÷ 26) | 0.007 | | Currently; (%) | 17 (32.07) | 16 (30.18) | 0.83 | | COPD; (%) | 6 (11.32) | 0 | 0.01 | | Familial history of cardiovascular diseases; (%) | 40 (75.47) | 29 (54.71) | 0.02 | | Medications | | | | | Aspirin; (%) | 53 (100) | 7 (13.2) | <0.00001 | | ACEI/ARB; (%) | 34 (64.15) | 10 (18.86) | <0.00001 | | β-blocker; (%) | 29 (54.71) | 12 (22.64) | 0.0007 | | Calcium channel blocker; (%) | 11 (20.75) | 3 (5.66) | 0.02 | | Diuretics; (%) | 5 (9.43) | 7 (13.2) | 0.53 | | Nitrates; (%) | 11 (20.75) | — | |
|
|
Data is presented as arithmetic means ± SD (min. ÷ max.); Student's -test; Chi2 test. Explanation of abbreviations used: ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, BMI: body-mass index, PCI: percutaneous coronary intervention, CAD: coronary artery disease, CABG: coronary artery bypass graft, and COPD: chronic obstructive pulmonary disease.
|
